Latest Observability News

Resolution Minerals Ltd has successfully raised $25.1 million through a heavily supported placement, positioning itself to advance its Horse Heaven Project in Idaho and prepare for a NASDAQ listing.

Tempest Minerals has secured regulatory approval to begin Phase I drilling at its Halo prospect within the Yalgoo Project, targeting iron, copper, and gold. A heritage survey with the Badimia People is currently in progress, marking a key step toward unlocking the site's potential.

Neurizon Therapeutics has raised $5 million through an institutional placement to advance its lead ALS drug candidate NUZ-001 into a pivotal clinical trial, pending FDA clearance. The capital injection also supports manufacturing and pre-clinical development efforts.

OncoSil Medical’s PANCOSIL Phase 1-2 study reveals promising safety and feasibility for a novel CT-guided pancreatic cancer therapy, with survival outcomes exceeding historical benchmarks.

Canterbury Resources has extended its 2025 Share Purchase Plan to 22 October, aiming to raise $0.75 million to advance exploration at its Jack Shay, Peenam, and Briggs copper projects.

Lord Resources has visually confirmed a significant 20.2-metre copper mineralisation interval at its Ilgarari Copper Project in Western Australia, highlighting promising signs of a supergene-enriched zone. Assay results are expected in October as drilling continues.

Greenvale Energy’s latest assays from its maiden drilling at the Oasis Uranium Project reveal continuous, near-surface high-grade uranium mineralisation, reinforcing the project’s promising potential.

Core Energy Minerals has confirmed uranium mineralisation at its Cummins Project in South Australia through a maiden aircore drilling program, reinforcing its geological model and setting the stage for targeted follow-up exploration.

CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.

Alterity Therapeutics has unveiled encouraging Phase 2 trial results for ATH434, demonstrating its potential to slow disease progression in Multiple System Atrophy while maintaining a strong safety profile.

Flynn Gold has initiated its first-ever diamond drilling program at the historically rich Double Event gold prospect in Northeast Tasmania, following trenching that revealed an extensive mineralised corridor. The drilling aims to validate and expand on promising surface assay results, potentially unlocking significant value for the Golden Ridge Project.

Altitude Minerals has secured drill permits and identified multiple high-priority copper-gold porphyry targets at its Byrock Project in NSW’s Macquarie Arc, with a 1,500m aircore and RC drill program planned for November 2025.